Outline of the EXAMINE Trial

Title: A Multicenter, Randomized, Double-Blind, Placebo- Controlled Study to Evaluate Cardiovascular Outcomes Following Treatment with Alogliptin in Addition to Standard of Care in Subjects with Type 2 Diabetes and Acute Coronary Syndrome Study Start: September 2009 Study Completion: December 2014 No. of Patients: Approximately 5,400 Primary Outcome: Time from randomization to the occurrence of the Primary Major Adverse Cardiac Events defined as a composite of cardiovascular death, nonfatal myocardial infarction and nonfatal stroke Secondary Outcome: Time from randomization to the occurrence of the Secondary Major Adverse Cardiac Events defined as a composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke and urgent revascularization due to unstable angina Study Sites: Approximately 1,000 sites in the U.S., Europe, Asia

Source: tpna